Advertisement

Journal of Clinical Immunology

, Volume 13, Issue 1, pp 58–67 | Cite as

Cytokine profile in systemic lupus erythematosus, rheumatoid arthritis, and other rheumatic diseases

  • Mansour Al-Janadi
  • Suliman Al-Balla
  • Abdullah Al-Dalaan
  • Syed Raziuddin
Original Articles

Abstract

We investigated serum levels of interleukin-6 (IL-6), interferon-gamma (IFN-γ), and tumor necrosis factor alpha (TNFα) from patients with systemic lupus erythematosus (SLE) and its various clinical manifestations of disease and from patients with rheumatoid arthritis (RA) and other rheumatic diseases. The serum levels of IL-6 and IFN-γ were highly elevated from patients with SLE associated with lymphadenopathy (LN) or nephrotic syndrome (NS). On the contrary, the serum levels of TNFα were elevated from most patients with SLE associated with thrombocytopenia (TP). However, serum levels of TNFα were in the normal range from patients with SLE associated with NS, LN, or central nervous system disease. Of interest, patients with SLE associated with humoral immunodeficiency disorder, hypogammaglobulinemia, had highly elevated levels of serum IL-6. The concanavalin A-stimulated mononuclear cells (MNC) of patients with SLE associated with TP secreted highly elevated levels of TNFα compared to other patient groups. We suggest that abnormal production of various cytokines in SLE is an intrinsic defect of MNC and the immune system that may be the key element for a variety of clinical manifestations of this disease.

Key words

Systemic lupus erythematosus rheumatoid arthritis, interleukin-6 interferon gamma tumor necrosis factor alpha 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Dinarello CA, Mier JW: Current concepts, lymphokines. N Engl J Med 317:940–945, 1987Google Scholar
  2. 2.
    Beutler B, Cerami A: The biology of cachectin/TNF—a primary mediator of the host response. Annu Rev Immunol 7:625–655, 1989Google Scholar
  3. 3.
    Kishimoto T: The biology of interleukin-6. Blood 74:1–10, 1989Google Scholar
  4. 4.
    Sneller MC, Strober W: Abnormalities of lymphokine gene expression in patients with common variable immunodeficiency. J Immunol 144:3762–3769, 1990Google Scholar
  5. 5.
    Schattner A, Lachini M, Livnen A, Pras M, Hahn T: Tumor necrosis factor in familial mediterranean fever. Am J Med 90:434–438, 1991Google Scholar
  6. 6.
    Linker-Israeli M, Deans RJ, Wallace DJ, Prehn J, Ozeri-Chen T, Klinberg JR: Elevated levels of endogenous IL-6 in systemic lupus erythematosus: A putative role in pathogenesis. J Immunol 147:117–123, 1991Google Scholar
  7. 7.
    Helfgott DC, Tatter SB, Santhanam U, Clarick RM, Bhardwaj N, May T, Sehgal PB: Multiple forms of IFN-B2/IL-6 in serum and body fluids during acute bacterial infection. J Immunol 142:948–953, 1989Google Scholar
  8. 8.
    Clark IA, Cowden WB, Butcher GA, Hunt NH: Possible role of tumor necrosis factor in the pathology of malaria. Am J Pathol 129:192–199, 1987Google Scholar
  9. 9.
    Barral-Netto M, Badaro R, Almeida R, Santos S, Badaro F, Falcoff R: Tumor necrosis factor (cachectin) in human visceral leishmaniasis. J Infect Dis 163:853–857, 1991Google Scholar
  10. 10.
    Akocer-Varela J, Aleman-Hoey D, Alarcon-Segovia D: Interleukin-1 and interleukin-6 are increased in the cerebrospinal fluid of patients with CNS lupus erythematosus and correlate with local late T cell activation markers. Lupus 1:111–117, 1992Google Scholar
  11. 11.
    Bhardwaj N, Santhanam U, Lau L, Tatter S, Ghrayed J, Rivelis M, Steinman R, Sehgal P, May L: IL-6/IFN-B2 in synovial effusion of patients with rheumatoid arthritis and other arthritides. Identification of several isoforms and studies of cellular sources. J Immunol 143:2153–2159, 1989Google Scholar
  12. 12.
    Schur PH, Sandson J: Immunologic factors and clinical activity in systemic lupus erythematosus. N Engl J Med 9:533–538, 1968Google Scholar
  13. 13.
    Smith HR, Steinberg AD: Autoimmunity—a perspective. Ann Rev Immunol 1:175–189, 1983Google Scholar
  14. 14.
    Tsokos GC, Margrath IT, Balow JE: Epstein-Barr virus induces normal B cell responses but defective suppressor T cell response in patients with systemic lupus erythematosus. J Immunol 131:1797–1801, 1983Google Scholar
  15. 15.
    Raziuddin S, Nur MA, Al-Wabel AA: Selective loss of the CD4+ inducers of suppressor T cell subsets (2H4+) in active systemic lupus erythematosus. J Rheumatol 16:1315–1319, 1989Google Scholar
  16. 16.
    Raziuddin S, Danial HB, Kelley M: OKT4 T cell abnormality in patients with systemic lupus erythematosus: HLA-DR antigen expressions. Clin Immunol Immunopathol 48:42–49, 1988Google Scholar
  17. 17.
    Fauci AS, Steinberg AD, Haynes BF, Whalen G: Immunoregulatory aberration in systemic lupus erythematosus. J Immunol 121:1473–1479, 1978Google Scholar
  18. 18.
    Campen DH, Horwitz DA, Quismorio FP, Ehresmann GR, Martin WJ: Serum levels of interleukin-2 receptor and activity of rheumatic diseases characterized by immune system activation. Arth Rheum 31:1358–1364, 1988Google Scholar
  19. 19.
    Wilson JG, Fearon DT: Altered expression of complement receptors as a pathogenetic factor in systemic lupus erythematosus. Arth Rheum 27:1321–1327, 1984Google Scholar
  20. 20.
    Morimoto C, Reinherz EL, Distaso JA, Steinberg AD, Schlossman SF: Relationship between systemic lupus erythematosus T cell subsets, anti-T cell antibodies and T cell functions. J Clin Invest 73:689–700, 1984Google Scholar
  21. 21.
    Raziuddin S, Al-Janadi MA, Al-Wabel AA: Soluble interleukin-2 receptor levels in serum and its relationship to T cell abnormality and clinical manifestations of the disease in patients with systemic lupus erythematosus. J Rheumatol 18:831–836, 1991Google Scholar
  22. 22.
    Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arth Rheum 25:271–1277, 1982Google Scholar
  23. 23.
    Arnett FC, Edworthy S, Block DA,et al.: The 1987 revised ARA criteria for rheumatoid arthritis. Arth Rheum 30:317, 1987Google Scholar
  24. 24.
    Talal N, Moutsopoulos HM, Kasan S: Sjogren's Syndrome. Heidelberg, Springer-Verlag, 1987Google Scholar
  25. 25.
    Bird HA, Esselinck W, Dixon AS, Mowat AG, Wood PHN: An evaluation of criteria for polymyalgia rheumatica. Ann Rheum Dis 38:434–439, 1979Google Scholar
  26. 26.
    Raziuddin S, Al-Janadi MA, Al-Wabel AA: T cell receptor alpha/beta chain-CD3 protein complex defect in systemic lupus erythematosus. T cell function. Am J Med 1992 (in press)Google Scholar
  27. 27.
    Scuderi P, Sterling K, Lam K, Finley P, Ryan K, Ray C, Peterson E, Slymen D, Salmon S: Raised serum levels of tumour necrosis factor in parasitic infections. Lancet 2:1364–1365, 1986Google Scholar
  28. 28.
    Tsokos GC, Smith PL, Balow JE: Development of hypogammaglobulinemia in a patient with systemic lupus erythematosus. Am J Med 81:1081–1084, 1986Google Scholar
  29. 29.
    Raziuddin S, Danial HB: OKT4+ T cell deficiency and an association of immunoglobulin deficiency in systemic lupus erythematosus. Clin Exp Immunol 72:466–469, 1988Google Scholar
  30. 30.
    Raziuddin S, Nur MA, Al-Janadi MA: CD4+ T lymphocyte deficiency and function in systemic lupus erythematosus and rheumatoid arthritis. Arth Rheum 33:1864–1865, 1990Google Scholar
  31. 31.
    Warrington RJ: B cell differentiation factor production in systemic lupus erythematosus. J Rheumatol 15:55–58, 1988Google Scholar
  32. 32.
    Abdou NI, Sagawa A, Rascual E, Habert J, Sadeghee S: Suppressor T cell abnormality in idiopathic systemic lupus erythematosus. Clin Immunol Immunopathol 6:192–199, 1976Google Scholar
  33. 33.
    Wolf RE, Brelsford WG: Soluble interleukin-2 receptors in systemic lupus erythematosus. Arth Rheum 31:729–735, 1988Google Scholar
  34. 34.
    Linker-Israeli M, Bakke AC, Kitridou RC, Gendler S, Gillis S, Horwitz DA: Defective production of interleukin-1 and interleukin-2 in patients with systemic lupus erythematosus. J Immunol 130:2651–2655, 1983Google Scholar
  35. 35.
    Houssiau FA, Devogelaer J-P, Van Damme J, Deuxchaisnes C, Van Snick J: Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arth Rheum 31:784–788, 1988Google Scholar
  36. 36.
    Firestein GS, Alvaro-Garcia JM, Maki R: Quantitative analysis of cytokine gene expression in rheumatoid arthritis. J Immunol 144:3347–3353, 1990Google Scholar
  37. 37.
    Dasgupta B, Panayi GS: Interleukin-6 in serum of patients with polymalgia rheumatica and giant cell arteritis. Br J Rheumatol 29:456–458, 1990Google Scholar
  38. 38.
    Linker-Israeli M: Cytokine abnormalities in human lupus. Clin Immunol Immunopathol 63:10–12, 1992Google Scholar
  39. 39.
    Alcocer-Varela J, Aleman-Hoey D, Alarcon-Segovia D: Interleukin-1, interleukin-6 activities are increased in the cerebrospinal fluid of patients with CNS lupus erythematosus and correlates with local late T-cell activation markers. Lupus 1:111–117, 1992Google Scholar

Copyright information

© Plenum Publishing Corporation 1993

Authors and Affiliations

  • Mansour Al-Janadi
    • 1
    • 2
    • 3
  • Suliman Al-Balla
    • 1
    • 2
    • 3
  • Abdullah Al-Dalaan
    • 1
    • 2
    • 3
  • Syed Raziuddin
    • 1
    • 2
    • 3
  1. 1.Department of Medicine, Department of Clinical ImmunologyKing Saud University, College of MedicineAbhaSaudi Arabia
  2. 2.Division of Rheumatology, Department of MedicineKing Saud University, College of MedicineRiyadhSaudi Arabia
  3. 3.King Faisal Specialist Hospital and Research CentreRiyadhSaudi Arabia

Personalised recommendations